Consequently, strategies to decrease the expression of alpha-synuclein in the enteric nervous system will be an attractive approach to prevent Parkinson’s disease progression at pre-clinical stages, before pathology can affect the brain and before clinical debut, in a subtype of Parkinson’s disease patients. Here, SNCA is linked to Parkinson disease.